Clinical effect on treatment of Buyang Huanwu Decoction combined with GP chemotherapy regimen in the treatment of advanced non-small cell lung cancer
WU Yiting1 QU Jinglian2 GUO Nannan1 ZHAO Feng1 LIU Yanwen1
1.Department of Internal Medicine Oncology, Jiangbei Branch of Zhongda Hospital, Southeast University, Jiangsu Province, Nanjing 210009, China;
2.College of Basic Medicine, Guiyang College of Traditional Chinese Medicine, Guizhou Provnice, Guiyang 550525, China
Abstract：Objective To investigate the effect of Buyang Huanwu Decoction combined with GP chemotherapy on hypercoagulability and quality of life in patients with advanced non-small cell lung cancer (NSCLC). Methods A total of 113 patients with NSCLC admitted to Zhongda Hospital, Southeast University from August 2016 to March 2018 were selected. The patients were divided into control group 56 cases and study group 57 cases by random number table method. The control group was given the chemotherapy regimen of Gemcitabine combined with Cisplatin (GP), and the study group was combined with Buyang Huanwu Decoction on the basis of the control group. The clinical efficacy, coagulation state and quality of life of the two groups were compared. Adverse reactions of the two groups were observed and compared. Results The total effective rate in the study group was significantly higher than the control group (P ＜ 0.05). After treatment, PLT, FIB, PT and APTT levels of the two groups decreased than those before treatment, and those in the study group were lower than the control group (P ＜ 0.05). The KPS scores of the two groups increased after treatment (P ＜ 0.05), and that in the study group was higher than the control group (P ＜ 0.01). The total incidence of adverse reactions in the study group was lower than the control group (P ＜ 0.01). Conclusion The combination of Buyang Huanwu Decoction combined with GP chemotherapy is effective and reliable in the treatment of advanced NSCLC. It can relieve the hypercoagulability and improve the quality of life, with few adverse reactions and high safety.
[1] Barth C，Soares M，Toffart AC，et al. Characteristics and outcome of patients with newly diagnosed advanced or metastatic lung canceradmitted to intensive care units（ICUs）[J]. Ann Intensive Care，2018，8（1）：80.
[2] 吴姗姗，严峰，邓玉玲，等.小细胞和非小细胞肺癌晚期患者CD3＋CD4＋及CD3＋CD8＋T淋巴细胞亚群的差异[J].中国免疫学杂志，2015，31（1）：114-116，121.
[3] 葛敏捷，虞敏，曹昕杨，等.人参多糖辅助GP化疗方案治疗非小细胞肺癌的有效性和安全性研究[J].中国生化药物杂志，2015，35（4）：132-134.
[4] 潘慧丽，曹焱.中医药内治法治疗肺癌的研究进展[J].中国生化药物杂志，2015，35（12）：183-185.
[5] 许珍珍.中医护理模式对中医保守治疗肺癌患者睡眠质量与生活质量的改善效果研究[J].湖北中医药大学学报，2018，20（1）：103-105.
[6] 董雯，李保玉，屈园利，等.补阳还五汤治疗脑梗死恢复期气虚血瘀证的Meta分析[J].中西医结合心脑血管病杂志，2016，14（6）：580-585.
[7] 支修益，吴一龙，马胜林，等.原发性肺癌诊疗规范（2011年版）[J].中国肺癌杂志，2012，15（12）：677-688.
[8] 邓日强，肖芸，刘清毅，等.非小细胞肺癌辅助化疗疗效与c-erbB-2、MRP、VEGF的关系[J].广东医学，2017，38（16）：2502-2505.
[9] Ooi KH，Cheo T，Soon GST，et al. Spontaneous regression of locally advanced nonsmall cell lung cancer：A case report [J]. Medicine（Baltimore），2018，97（31）：e112 91.
[10] 王洪玲，李琳，王键玮，等.小细胞肺癌预后因子的研究进展[J].中国医药导报，2017，14（12）：56-59.
[11] Gibson AJW，Li H，D'Silva A，et al. Impact of number versus location of metastases on survival in stage Ⅳ M1b non-small cell lung cancer [J]. Med Oncol，2018，35（9）：117.
[12] 吕群，张刘海，余瑜曼，等.低分子肝素联合参麦注射液对老年晚期非小细胞肺癌患者高凝状态的影响[J].中国老年学杂志，2017，37（21）：5334-5336.
[13] 韩啸东，张侠，刘畅，等.非小细胞肺癌患者血液高凝状态的临床调查[J].现代生物医学进展，2015，15（5）：882-886，877.
[14] McGowan DR，Skwarski M，Papiez BW，et al. Whole tumor kinetics analysis of 18F-fluoromisonidazole dynamic PET scans of non-small cell lung cancer patients，and correlations with perfusion CT blood flow [J]. EJNMMI Res，2018，8（1）：73.
[15] 黄琬玲，周燕斌，黎银焕，等.血浆组织因子在非小细胞肺癌患者中的表达及意义[J].中国综合临床，2013，29（3）：246-249.
[16] Afzal MZ，Dragnev K，Shirai K. Atertiary care cancer center experience with carboplatin and pemetrexed in combination with pembrolizumab in comparison with carboplatin and pemetrexed alone in non-squamous non-small cell lung cancer [J]. J Thorac Dis，2018，10（6）：3575-3584.
[17] 孔斌.不同含铂治疗方案在晚期非小细胞肺癌患者中的应用效果[J].中国医药导报，2016，13（35）：102-105.
[18] 陈文军，田菲，许冬鑫，等.非小细胞肺癌患者预后影响因素与中医体质类型的相关性[J].中医杂志，2015，56（18）：1569-1572.
[19] 罗银河，葛金文，刘林，等.补阳还五汤治疗缺血性中风临床应用进展[J].中西医结合心脑血管病杂志，2016， 14（3）：278-281.
[20] 张翔，周建伟，顾芳红，等.补阳还五汤治疗中晚期非小细胞肺癌血液高凝状态的疗效观察[J].实用肿瘤学杂志，2013，27（5）：414-416.
[21] 袁磊，杨进平，闻瑛，等.补阳还五汤治疗缺血性中风恢复期（气虚血瘀）的临床疗效及对Hcy影响的临床研究[J].中华中医药学刊，2016，34（1）：195-197.
[22] 张翔，朱斌，周建伟，等.补阳还五汤联合化疗治疗中晚期非小细胞肺癌的疗效[J].求医问药：学术版，2012，10（11）：606-607.
[23] 董浙清，毛向红，楼黎明，等.补阳还五汤对家兔血管内皮损伤后血小板源性生长因子受体和原癌基因表达的影响[J].中国基层医药，2012，19（7）：1011-1012.
2018, Vol. 15 
京公网安备 11010502046598号